Skip to content

The effectiveness of ketamine on suicidal ideation

Comparing the effectiveness of ketamine and placebo on suicidal ideation

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190317043079N4
Enrollment
90
Registered
2023-04-25
Start date
2023-04-25
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder. Mood disorder due to known physiological condition with major depressive-like episode

Interventions

Intervention 1: Intervention group: Ketamine with a dose of 0.75-0.50 mg/kg as a 40-minute infusion. Intervention 2: Control group: 0.9% saline as a 40-minute infusion.

Sponsors

Babol University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: having a major depressive episode based on a clinical interview (based on DSM-5) A total score of more than 5 on the Beck suicidal ideation scale A score of 14 or higher in the Beck depression questionnaire Absence of pregnancy or lactation Absence of obvious cognitive impairment or mental retardation

Exclusion criteria

Exclusion criteria: Receiving psychiatric medications within a month before starting ketamine treatment History of sensitivity to ketamine

Design outcomes

Primary

MeasureTime frame
Suicidal Ideation. Timepoint: 48 hours after receiving the infusion. Method of measurement: Beck scale suicide ideation questionaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzan Kheirkhah

Babol University of Medical Sciences

f.kheirkhah@mubabol.ac.ir+98 11 3233 8301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026